Details
Stereochemistry | ACHIRAL |
Molecular Formula | C21H19F2N3O3 |
Molecular Weight | 399.3907 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOCN1C2=CC(F)=CC=C2N3CCC(=O)C(C(=O)NC4=C(F)C=CC=C4)=C13
InChI
InChIKey=VQOQDABVGWLROX-UHFFFAOYSA-N
InChI=1S/C21H19F2N3O3/c1-2-29-12-26-17-11-13(22)7-8-16(17)25-10-9-18(27)19(21(25)26)20(28)24-15-6-4-3-5-14(15)23/h3-8,11H,2,9-10,12H2,1H3,(H,24,28)
Molecular Formula | C21H19F2N3O3 |
Molecular Weight | 399.3907 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 17:06:57 GMT 2025
by
admin
on
Tue Apr 01 17:06:57 GMT 2025
|
Record UNII |
NNJ1LL72JS
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
NNJ1LL72JS
Created by
admin on Tue Apr 01 17:06:57 GMT 2025 , Edited by admin on Tue Apr 01 17:06:57 GMT 2025
|
PRIMARY | |||
|
205701-85-5
Created by
admin on Tue Apr 01 17:06:57 GMT 2025 , Edited by admin on Tue Apr 01 17:06:57 GMT 2025
|
PRIMARY | |||
|
DTXSID90431349
Created by
admin on Tue Apr 01 17:06:57 GMT 2025 , Edited by admin on Tue Apr 01 17:06:57 GMT 2025
|
PRIMARY | |||
|
9822240
Created by
admin on Tue Apr 01 17:06:57 GMT 2025 , Edited by admin on Tue Apr 01 17:06:57 GMT 2025
|
PRIMARY | |||
|
RWJ-51204
Created by
admin on Tue Apr 01 17:06:57 GMT 2025 , Edited by admin on Tue Apr 01 17:06:57 GMT 2025
|
PRIMARY | RWJ-51204 is an anxiolytic drug used in scientific research. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic. RWJ-51204 is a nonselective partial agonist at GABAA receptors. It produces primarily anxiolytic effects at low doses, with sedative, ataxia and muscle relaxant effects only appearing at some 20x the effective anxiolytic dose.(2) It was discovered by researchers at the pharmaceutical company Johnson & Johnson, but its development has been discontinued. |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET->PARTIAL AGONIST |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |